ArticleInternational journal of general medicine2026
Cholesterol-to-Lymphocyte Ratio as a Predictor of 1-Year Unplanned Readmission in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) face a markedly increased risk of unplanned readmission due to metabolic disturbances and chronic inflammation. The cholesterol-to-lymphocyte ratio (CLR), reflecting both dyslipidemia and inflammatory status, may serve as a useful marker for risk stratification. This study aimed to evaluate the predictive value of CLR for 1-year unplanned readmission in CAD patients with T2DM. Methods: We conducted a single-center retrospective cohort study of patients hospitalized from January to December 2023 who were diagnosed with CAD and T2DM by coronary angiography. Demographic characteristics, comorbidities, medication use, and laboratory findings were collected, and CLR was calculated. Least absolute shrinkage and selection operator (LASSO) regression was applied to identify key predictors. Logistic regression, multilayer perceptron (MLP), and extreme gradient boosting (XGBoost) models were developed to assess predictive performance. Model discrimination and calibration were evaluated using AUC, accuracy, sensitivity, specificity, and calibration curves. Variable importance was further explored with SHAP value analysis. Results: A total of 973 patients were included, comprising 769 without readmission (NRG) and 204 with readmission (RG). CLR was significantly higher in the RG group (3.63 vs 3.07, P < 0.001). Six predictors were selected by LASSO: sex, age, atrial fibrillation, β-blocker use, oral anticoagulant use, and CLR. Among the models, XGBoost achieved the best performance in the test set (AUC = 0.81, accuracy = 0.72) with good calibration. SHAP analysis identified CLR as the most influential variable (mean absolute SHAP = 0.42), contributing most strongly to readmission risk. Regular outpatient use of β-blockers and oral anticoagulants was protective, while atrial fibrillation, younger age, and female sex were associated with increased risk. Conclusion: CLR showed a moderate ability to assist risk prediction of 1-year unplanned readmission in patients with CAD and T2DM in this exploratory single-center study. Further external validation is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.